Fortress Biotech Management
Management criteria checks 3/4
Fortress Biotech's CEO is Lindsay Rosenwald, appointed in Dec 2013, has a tenure of 10.08 years. total yearly compensation is $1.74M, comprised of 3.6% salary and 96.4% bonuses, including company stock and options. directly owns 15.9% of the company’s shares, worth €6.46M. The average tenure of the management team and the board of directors is 9.9 years and 9.9 years respectively.
Key information
Lindsay Rosenwald
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 3.6% |
| CEO tenure | 10.1yrs |
| CEO ownership | 15.9% |
| Management average tenure | 9.9yrs |
| Board average tenure | 9.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$78m |
| Jun 30 2023 | n/a | n/a | -US$96m |
| Mar 31 2023 | n/a | n/a | -US$92m |
| Dec 31 2022 | US$2m | US$63k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$97m |
| Jun 30 2022 | n/a | n/a | -US$93m |
| Mar 31 2022 | n/a | n/a | -US$74m |
| Dec 31 2021 | US$3m | US$60k | -US$65m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$33m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$3m | US$59k | -US$47m |
| Sep 30 2020 | n/a | n/a | -US$57m |
| Jun 30 2020 | n/a | n/a | -US$54m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$1m | US$32k | -US$40m |
| Sep 30 2019 | n/a | n/a | -US$45m |
| Jun 30 2019 | n/a | n/a | -US$51m |
| Mar 31 2019 | n/a | n/a | -US$53m |
| Dec 31 2018 | US$2m | US$31k | -US$73m |
| Sep 30 2018 | n/a | n/a | -US$61m |
| Jun 30 2018 | n/a | n/a | -US$69m |
| Mar 31 2018 | n/a | n/a | -US$72m |
| Dec 31 2017 | US$2m | US$31k | -US$65m |
Compensation vs Market: Lindsay's total compensation ($USD1.74M) is above average for companies of similar size in the German market ($USD416.08K).
Compensation vs Earnings: Lindsay's compensation has been consistent with company performance over the past year.
CEO
Lindsay Rosenwald (68 yo)
10.1yrs
Tenure
US$1,741,416
Compensation
Dr. Lindsay Allan Rosenwald, M.D., serves as Director of Urica Therapeutics, Inc. He serves as Director at Caelum Biosciences, Inc. He serves as an Executive Chairman of Journey Medical Corporation since O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 10.1yrs | US$1.74m | 15.9% $ 6.5m | |
| Vice Chairman & Executive Vice Chairman of Strategic Development | 10.1yrs | US$966.56k | 7.33% $ 3.0m | |
| CFO & Head of Corporate Development | 3.7yrs | US$2.03m | 0.032% $ 13.1k | |
| Senior Vice President of Biologics Operations | 10.6yrs | US$386.49k | 0.24% $ 96.6k | |
| General Counsel & Corporate Secretary | 5.3yrs | no data | no data |
9.9yrs
Average Tenure
62.5yo
Average Age
Experienced Management: CNB1's management team is seasoned and experienced (9.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 14.3yrs | US$1.74m | 15.9% $ 6.5m | |
| Vice Chairman & Executive Vice Chairman of Strategic Development | 10.1yrs | US$966.56k | 7.33% $ 3.0m | |
| Independent Director | 9.9yrs | US$160.00k | 0.031% $ 12.6k | |
| Independent Director | 8.5yrs | US$350.00k | 0.069% $ 28.2k | |
| Scientific Advisor | 6.6yrs | no data | no data | |
| Co-Vice Chairman | 13.3yrs | US$479.25k | 0.27% $ 107.9k | |
| Independent Director | 17.6yrs | US$317.50k | 0.63% $ 255.9k | |
| Director | 1.1yrs | US$576.27k | 0.018% $ 7.1k | |
| Scientific Advisor | 6.6yrs | no data | no data | |
| Scientific Advisor | 6.6yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 15.1yrs | US$297.50k | 0.018% $ 7.4k |
9.9yrs
Average Tenure
63yo
Average Age
Experienced Board: CNB1's board of directors are considered experienced (9.9 years average tenure).